Subscribe to Updates in Healthcare

RSS By Email

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines


The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

All GLG News Analyses Filed Under: Business of Medicine

Articles with lock require a GLG News subscription
Posted April 11, 2008
The Vytorin Saga Continues: Krumholz Strikes Back
Analysis of: The Vytorin Saga Continues: Krumholz Strikes Back | www.pharmalot.com
Author: GLG Member Program Contributor
The treatment of hyperlipidemia has profound repercussions on cardiovascular disease. The market is huge. I hear that there were 35 million prescriptions for ezetimibe products last year. Although the epidemiological association between LDL and cardiac risk is strong, LDL is an imperfect surrogate for...
Posted April 10, 2008
Takeda to Buy Millennium In $8.8 Billion Deal
Analysis of: Takeda to Buy Millennium In $8.8 Billion Deal | online.wsj.com
Author: GLG Member Program Contributor
Japan's biggest (by revenue) drug manufacturer has placed a bid For Millennium and it's primary product Velcade.
Posted April 9, 2008
House OKs Limits on Health Insurance
Analysis of: House OKs Limits on Health Insurance | www.post-gazette.com
Author: GLG Member Program Contributor
Pennsylvania is a bell weather for hospital reporting in the US.  The "hospital costing containment council" (I forget the name) is famous for highlighting percentage of patients acquiring hospital infections after arrival.  Accountability for these very high costs lay with people managing...
Posted April 8, 2008
The Vytorin Saga Continues: Krumholz Strikes Back
Analysis of: The Vytorin Saga Continues: Krumholz Strikes Back | www.pharmalot.com
Author: GLG Member Program Contributor
Development of plaque in arteries takes place over a lifetime.  There have been studies suggesting plaque removal can happen over shorter periods, but data demonstration that this solves medical problems is not available.  Complicatons like heart attacks come from the unstable plaque...
Posted April 8, 2008
Investor chief questions role of Big Pharma in development of medicines
Analysis of: Investor chief questions role of Big Pharma in development of medicines | business.timesonline.co.uk
Author: GLG Member Program Contributor
Larger R&D is important to developing products which have large capital requirements and need for large groups.  Smaller groups can act much faster when developing products with managable resouce needs.  Smaller groups working independently from a large corporation have several...
Posted April 8, 2008
Consumers, Health Care Purchasers, Physicians, and Health Insurers Announce Agreement on Principles to Guide Physician Performance Reporting
Analysis of: Consumers, Health Care Purchasers, Physicians, and Health Insurers Announce Agreement on Principles to Guide Physician Performance Reporting | www.cyperus.com
Author: GLG Member Program Contributor
Leading consumer, employer and labor organizations have agreed with the top medical and health insurance groups on principles to govern the development of physician performance measures.  The "Patient Charter for Physician Performance Measurement, Reporting and Tiering Programs" creates a national...
Posted April 8, 2008
Will Insurers Reduce Coverage For Vytorin?
Analysis of: Will Insurers Reduce Coverage For Vytorin? | www.pharmalot.com
Author: GLG Member Program Contributor
I believe insurers and pharmacy benefit management companies will coverage of Vytorin.  Most likely, it will lose any preferred status, (formulary Tier 2), and move to non-preferred brand, (formulary Tier 3 or Tier 4), depending on the drug reimbursement system in the health plan.  As an example,...
Posted April 8, 2008
Venture Activity Hit by U.S. Slowdown
Analysis of: Venture Activity Hit by U.S. Slowdown | online.wsj.com
Author: GLG Member Program Contributor
As a partner @ a VC fund I  see this trend impacting how potential portfolio companies are evaluated.  Companies that will have a future acquisition, as an liquidity event, will have a higher probability of being funded.  Investment decisons are also being influenced by the potential...
Adam Fein Posted April 8, 2008
Surprising Growth by Independent Pharmacies
Analysis of: IMS Health Reports U.S. Prescription Sales Grew 3.8 Percent in 2007, to $286.5 Billion | www.imshealth.com
Author: Adam Fein, Founder & President Pembroke Consulting Inc
According to IMS, independent pharmacies were the fastest growing pharmacy channel in 2007.  In fact, independents grew more than 5 times as fast as chains.  This growth is surprising given the heated rhetoric around the “debilitating consequences” of Part D, Wal-Mart’s “predatory pricing,”...
Robert Forster Posted April 8, 2008
Education is over rated regarding pharmaceuticals
Analysis of: Rx Watchdog Report: Trends in Manufacturer Prices of Brand Name Prescription Drugs Used by Medicare Beneficiaries—2002-2007 | www.aarp.org
Author: Robert Forster, Healthcare Consultant Robert Forster, MD
If I may, Mr. Goldstein suggests that education to providers re: cost/benefit or value will drive drug selection.  I disagree in that there are may barriers to provider (most physicians) behavior and their selection of drugs.  To mention a few are as follows:  1. My anecdotal experience...
Previous Page : 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 Next181 to 190 of 564

More GLG News in
Healthcare

Most Popular:
Source Article | Expert Analyses
 

GLG News: What Experts Think Is Important





Analytics